These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6744243)

  • 1. Inhibition by N-(phosphonacetyl)-L-aspartate of Ehrlich ascites tumour growth and glucose transport.
    Leung SW; Fung KP; Choy YM; Lee CY
    Cancer Lett; 1984 Jun; 23(2):183-8. PubMed ID: 6744243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of radiolabeled N-(phosphonacetyl)-L-aspartate to aspartate transcarbamylase from Ehrlich ascites tumor cells.
    White JC; Hines LH
    Biochem Pharmacol; 1984 Nov; 33(22):3645-8. PubMed ID: 6508821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human tumour necrosis factor-alpha inhibits glucose transport in cultured Ehrlich ascites tumour cells.
    Fung KP; Lam WP; Choy YM; Lee CY
    Life Sci; 1995; 57(1):PL1-6. PubMed ID: 7541099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of endocytosis and lysosomal pH in uptake of N-(phosphonacetyl)-L-aspartate and its inhibition of pyrimidine synthesis.
    White JC; Hines LH
    Cancer Res; 1984 Feb; 44(2):507-13. PubMed ID: 6692357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
    Erlichman C
    Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
    Johnson RK; Swyryd EA; Stark GR
    Cancer Res; 1978 Feb; 38(2):371-8. PubMed ID: 620408
    [No Abstract]   [Full Text] [Related]  

  • 7. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Ardalan B; Jayaram HN; Johnson RK
    Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
    Jayaram HN; Cooney DA; Vistica DT; Kariya S; Johnson RK
    Cancer Treat Rep; 1979 Aug; 63(8):1291-302. PubMed ID: 476706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose transport in developing Ehrlich ascites tumor cells: parallel changes in the rate of glucose uptake and cytochalasin B binding activity during tumor development and methotrexate treatment.
    Chan TW; Fung KP; Choy YM; Lee CY
    Arch Biochem Biophys; 1983 Sep; 225(2):458-66. PubMed ID: 6625594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
    Van Echo DA; Diggs CH; Scoltock M; Wiernik PH
    Cancer Treat Rep; 1980; 64(2-3):339-42. PubMed ID: 7407767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
    Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
    Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
    [No Abstract]   [Full Text] [Related]  

  • 12. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
    Grem JL; King SA; O'Dwyer PJ; Leyland-Jones B
    Cancer Res; 1988 Aug; 48(16):4441-54. PubMed ID: 3293772
    [No Abstract]   [Full Text] [Related]  

  • 13. Response of psoriasis to N-phosphonacetyl-L-aspartate.
    Earhart RH; DeConti RC; Rubin J; Ohnuma T
    Lancet; 1981 Jun; 1(8232):1257-8. PubMed ID: 6112581
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
    Karle JM; Anderson LW; Erlichman C; Cysyk RL
    Cancer Res; 1980 Aug; 40(8 Pt 1):2938-40. PubMed ID: 7388844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
    Carroll DS; Gralla RJ; Kemeny NE
    Cancer Treat Rep; 1980; 64(2-3):349-51. PubMed ID: 7407769
    [No Abstract]   [Full Text] [Related]  

  • 16. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
    Monks A; Anderson LW; Strong J; Cysyk RL
    J Biol Chem; 1983 Nov; 258(22):13564-9. PubMed ID: 6417130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Kovach JS; Schutt AJ; Moertel CG; O'Connell MJ
    Cancer Treat Rep; 1979; 63(11-12):1909-12. PubMed ID: 526923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The reversal of effects of methotrexate on toxicity and glucose transport reduction by thymidine in Ehrlich ascites tumor bearing mice.
    Fung KP; Ng SW; Choy YM
    Cancer Biochem Biophys; 1986 Oct; 8(4):249-56. PubMed ID: 3802046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of psoriasis with N-phosphonacetyl-L-aspartate.
    Doyle JA; Perry HO; Rubin J; Moertel CG
    J Am Acad Dermatol; 1984 Jan; 10(1):21-4. PubMed ID: 6229552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective enhancement of 5-fluorouridine uptake and action in rat hepatomas in vivo following pretreatment with D-galactosamine and 6-azauridine or N-(phosphonacetyl)-L-aspartate.
    Anukarahanonta T; Holstege A; Keppler DO
    Eur J Cancer (1965); 1980 Sep; 16(9):1171-80. PubMed ID: 6164559
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.